^
Association details:
| Biomarker: | EML4-ALK variant 3 |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EML4-ALK oncogenic fusion proteins: impact on mitotic progression and sensitivity to anti-microtubule drugs
Published date:
05/28/2021
Excerpt:
Patient-derived cell lines expressing EML4-ALK V1 (H3122) or V3 (H2228) were analysed by immunofluorescence microscopy….H2228 cells showed increased mitotic defects and reduced SAC activity in response to anti-microtubule drugs….These cells are sensitive to the anti-mitotic drug paclitaxel...
